Law360 (January 30, 2009, 12:00 AM EST) -- Weeks after Eli Lilly & Co. announced a record-breaking $1.4 billion deal to settle charges that it illegally marketed its anti-psychotic treatment Zyprexa for off-label use, the pharmaceutical giant formally pled guilty Friday to a misdemeanor related to the scandal.
The U.S. Attorney's Office for the Eastern District of Pennsylvania said Lilly — which had already agreed to the plea — officially pled guilty at a hearing in federal court in Philadelphia to "the introduction into interstate commerce of quantities of its drug, Zyprexa, that were misbranded," in violation of federal rules.
Specifically, the Indiana-based company pled guilty to promoting Zyprexa...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!